RELB and B-cell chronic lymphocytic leukemia: We exploited this characteristic to confirm the role of NF-κB in EZH2 induction in CLL cells: treatment with the IKKβ inhibitor TPCA-1 efficiently blocked the induction of NF-κB2/RelB protein and mRNA levels and also abolished induction of EZH2 (Fig. 2C & D).